Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Frank Arnold

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0025-3668; OpenAlex author ID A5044380940. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2020: 4 papers · 2021: 3 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 3 papers

Papers 10

  1. DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer. Co-author DOI 10.1002/advs.202417606↗
  2. A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-026-48584-2↗
  3. ATM Deficiency Induces TGFβ-Mediated Stromal Programming in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-0138↗
  4. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-319970↗
  5. RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-2633↗
  6. Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. Co-author DOI 10.3390/cancers13133145↗
  7. A feedback-loop between telomerase activity and stemness factors regulates PDAC stem cells Co-author DOI 10.1101/2020.11.02.361931↗
  8. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. Co-author DOI 10.1177/2050640620905183↗
  9. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy. Co-author DOI 10.3390/cells9092110↗
  10. An Immunological Glance on Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/ijms21093345↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alexander Kleger · 10 shared papers, 2020–2026 · strength 1.30
  2. Thomas Theodor Werner Seufferlein · 10 shared papers, 2020–2026 · strength 1.30
  3. Johann Gout · 6 shared papers, 2020–2026 · strength 0.78
  4. Lukas Perkhofer · 6 shared papers, 2020–2026 · strength 0.78
  5. Patrick Christian Hermann · 6 shared papers, 2020–2026 · strength 0.76
  6. Élodie Roger · 5 shared papers, 2020–2026 · strength 0.69
  7. Karolin Walter · 6 shared papers, 2020–2026 · strength 0.68
  8. Bruno Sáinz · 5 shared papers, 2020–2026 · strength 0.58
  9. Michael Karl Melzer · 3 shared papers, 2020–2026 · strength 0.52
  10. Pierre‐Olivier Frappart · 5 shared papers, 2020–2021 · strength 0.44
  11. Kanishka Tiwary · 3 shared papers, 2020–2026 · strength 0.41
  12. Dharini Srinivasan · 2 shared papers, 2026 · strength 0.40
  13. Matthias J. Löhr · 2 shared papers, 2026 · strength 0.40
  14. Elisabeth Heßmann · 2 shared papers, 2021–2026 · strength 0.32
  15. Martin Müller · 3 shared papers, 2020–2021 · strength 0.28
  16. Roland Rad · 2 shared papers, 2021–2026 · strength 0.27
  17. Eva Rodríguez-Aznar · 3 shared papers, 2020–2021 · strength 0.27
  18. Sonia Alcalá · 1 shared paper, 2026 · strength 0.23
  19. Anton Lahusen · 1 shared paper, 2026 · strength 0.23
  20. Chantal Allgöwer · 1 shared paper, 2026 · strength 0.22
  21. Peter Möller · 1 shared paper, 2026 · strength 0.22
  22. Alica K. Beutel · 2 shared papers, 2020 · strength 0.19
  23. Hans Armin Kestler · 2 shared papers, 2021 · strength 0.19
  24. Thomas Jens Ettrich · 2 shared papers, 2020–2021 · strength 0.18
  25. Christopher J. Halbrook · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.